[go: up one dir, main page]

RU2017146408A3 - - Google Patents

Download PDF

Info

Publication number
RU2017146408A3
RU2017146408A3 RU2017146408A RU2017146408A RU2017146408A3 RU 2017146408 A3 RU2017146408 A3 RU 2017146408A3 RU 2017146408 A RU2017146408 A RU 2017146408A RU 2017146408 A RU2017146408 A RU 2017146408A RU 2017146408 A3 RU2017146408 A3 RU 2017146408A3
Authority
RU
Russia
Application number
RU2017146408A
Other versions
RU2733741C2 (ru
RU2017146408A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017146408A publication Critical patent/RU2017146408A/ru
Publication of RU2017146408A3 publication Critical patent/RU2017146408A3/ru
Application granted granted Critical
Publication of RU2733741C2 publication Critical patent/RU2733741C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/02Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/02Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2
    • C07D317/06Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2 condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
RU2017146408A 2015-05-29 2016-05-27 Тетразамещенные алкеновые соединения и их применение RU2733741C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562168529P 2015-05-29 2015-05-29
US201562168581P 2015-05-29 2015-05-29
US62/168,581 2015-05-29
US62/168,529 2015-05-29
US201562269745P 2015-12-18 2015-12-18
US62/269,745 2015-12-18
PCT/US2016/034782 WO2016196346A1 (en) 2015-05-29 2016-05-27 Tetrasubstituted alkene compounds and their use

Publications (3)

Publication Number Publication Date
RU2017146408A RU2017146408A (ru) 2019-07-02
RU2017146408A3 true RU2017146408A3 (ru) 2019-10-18
RU2733741C2 RU2733741C2 (ru) 2020-10-06

Family

ID=57398096

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017146408A RU2733741C2 (ru) 2015-05-29 2016-05-27 Тетразамещенные алкеновые соединения и их применение

Country Status (34)

Country Link
US (2) US9796683B2 (ru)
EP (2) EP3981766A1 (ru)
JP (1) JP6325760B1 (ru)
KR (1) KR102664618B1 (ru)
CN (2) CN107847498B (ru)
AU (1) AU2016271126B2 (ru)
BR (1) BR112017025546B1 (ru)
CA (1) CA2987321C (ru)
CL (1) CL2017002996A1 (ru)
CO (1) CO2017013432A2 (ru)
CY (1) CY1125068T1 (ru)
DK (1) DK3302471T3 (ru)
ES (1) ES2895511T3 (ru)
HR (1) HRP20211542T1 (ru)
HU (1) HUE056199T2 (ru)
IL (1) IL255765B2 (ru)
JO (1) JO3735B1 (ru)
LT (1) LT3302471T (ru)
MA (1) MA43364B1 (ru)
MD (1) MD3302471T2 (ru)
MX (1) MX379297B (ru)
MY (1) MY186977A (ru)
PE (1) PE20181083A1 (ru)
PH (1) PH12017502142B1 (ru)
PL (1) PL3302471T3 (ru)
PT (1) PT3302471T (ru)
RS (1) RS62481B1 (ru)
RU (1) RU2733741C2 (ru)
SI (1) SI3302471T1 (ru)
SM (1) SMT202100599T1 (ru)
TW (1) TWI704137B (ru)
UA (1) UA120882C2 (ru)
WO (2) WO2016196346A1 (ru)
ZA (1) ZA201707912B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA120882C2 (uk) 2015-05-29 2020-02-25 ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. Тетразаміщені алкенові сполуки і їх застосування
EP3544974A1 (en) * 2016-11-24 2019-10-02 Eisai R&D Management Co., Ltd. Tetrasubstituted alkene compounds and their use for the treatment of breast cancer
WO2018098251A1 (en) * 2016-11-24 2018-05-31 Eisai R&D Management Co., Ltd. Tetrasubstituted alkene compounds and their use
MX385930B (es) * 2016-11-28 2025-03-18 Eisai R&D Man Co Ltd Sales de derivado de indazol y cristales de las mismas.
US11083722B2 (en) 2017-03-16 2021-08-10 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer
MX2020012066A (es) 2018-05-14 2021-04-28 Nuvation Bio Inc Compuestos anticancerígenos dirigidos a los receptores hormonales nucleares.
WO2019225552A1 (en) * 2018-05-22 2019-11-28 Eisai R&D Management Co., Ltd. Salts of indazole derivative and crystals thereof
SG11202106401UA (en) 2018-12-17 2021-07-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Estrogen receptor antagonist
MX2021013774A (es) * 2019-05-14 2021-12-10 Nuvation Bio Inc Compuestos anticancerigenos dirigidos a los receptores hormonales nucleares.
KR20220012891A (ko) 2019-05-24 2022-02-04 에자이 알앤드디 매니지먼트 가부시키가이샤 에스트로겐 수용체-알파 억제제의 경구 투여 형태로 암을 치료하는 방법
JP2022537330A (ja) * 2019-06-19 2022-08-25 江蘇恒瑞医薬股▲ふん▼有限公司 インダゾール誘導体、その製造方法及び医薬上のその使用
CN110452177A (zh) * 2019-09-02 2019-11-15 南通大学 一种5-溴-4-氟-1h-吲唑的合成方法
TW202131930A (zh) 2019-11-13 2021-09-01 美商諾維雪碧歐公司 抗癌核荷爾蒙受體標靶化合物
US12415799B2 (en) 2020-06-28 2025-09-16 Zhejiang Yangli Pharmaceutical Technology Co., Ltd. Indazole-fused cyclic compound
EP4240357A1 (en) * 2020-11-06 2023-09-13 Eisai R&D Management Co., Ltd. Method of treating breast cancer
CN114644615B (zh) * 2020-12-18 2023-11-14 江苏恒瑞医药股份有限公司 一种吲唑类衍生物的结晶形式及其制备方法
CN116615418B (zh) * 2020-12-18 2025-11-11 江苏恒瑞医药股份有限公司 一种吲唑类衍生物的药学上可接受的盐、结晶形式及其制备方法
CN114644616B (zh) * 2020-12-18 2023-11-14 江苏恒瑞医药股份有限公司 一种吲唑类衍生物的药学上可接受的盐、结晶形式及其制备方法
IL306010A (en) 2021-03-23 2023-11-01 Nuvation Bio Inc Anticancer compounds against the nuclear hormone receptor
AU2022269568A1 (en) 2021-05-03 2023-11-16 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN117440950A (zh) * 2021-06-27 2024-01-23 北京盛诺基医药科技股份有限公司 一种ERα受体共价结合拮抗剂
CN115960082B (zh) * 2021-10-13 2024-06-07 长春金赛药业有限责任公司 一种四取代的烯烃化合物、其制备方法及其在医药上的应用
CN117550980B (zh) * 2023-12-04 2025-12-19 宁夏瑞泰科技股份有限公司 一种制备n-乙基-1,6-己二胺的方法和由其制得的产品

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3907290A1 (de) 1989-03-07 1990-09-13 Gerhard Prof Dr Eisenbrand Steroidhormonrezeptoraffine antitumorwirkstoffe
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
WO2007058626A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
WO2009120999A2 (en) 2008-03-28 2009-10-01 Olema Pharmaceuticals, Inc. Use of an endoxifen prodrug for treatment of breast cancer
US8063249B1 (en) 2008-04-25 2011-11-22 Olema Pharmaceuticals, Inc. Substituted triphenyl butenes
CA2775266C (en) 2009-10-13 2013-12-31 Duquesne University Of The Holy Spirit, A Nonprofit Corporation Organized Under The Laws Of The Commonwealth Of Pennsylvania Anti-cancer tamoxifen-melatonin hybrid ligand
WO2011129837A1 (en) 2010-04-16 2011-10-20 Olema Pharmaceuticals, Inc. Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
WO2013056178A2 (en) 2011-10-14 2013-04-18 Foundation Medicine, Inc. Novel estrogen receptor mutations and uses thereof
NZ630124A (en) 2012-03-20 2016-01-29 Seragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
US9365510B2 (en) 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
CN105451735B (zh) 2013-06-19 2019-01-11 西拉根制药公司 氮杂环丁烷雌激素受体调节剂和其用途
JP6576916B2 (ja) 2013-06-19 2019-09-18 セラゴン ファーマシューティカルズ, インク. エストロゲン受容体モジュレーター及びその使用
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
SG11201607334YA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
WO2016055982A1 (en) 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
UA120882C2 (uk) 2015-05-29 2020-02-25 ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. Тетразаміщені алкенові сполуки і їх застосування

Also Published As

Publication number Publication date
WO2016196346A1 (en) 2016-12-08
ES2895511T3 (es) 2022-02-21
TWI704137B (zh) 2020-09-11
IL255765B2 (en) 2023-10-01
SMT202100599T1 (it) 2021-11-12
UA120882C2 (uk) 2020-02-25
RS62481B1 (sr) 2021-11-30
AU2016271126A1 (en) 2017-12-07
PL3302471T3 (pl) 2022-02-07
CL2017002996A1 (es) 2018-03-23
MD3302471T2 (ro) 2021-12-31
EP3302471A4 (en) 2018-10-10
AU2016271126B2 (en) 2020-09-24
CY1125068T1 (el) 2023-03-24
HUE056199T2 (hu) 2022-01-28
CN107847498A (zh) 2018-03-27
BR112017025546B1 (pt) 2023-02-14
PT3302471T (pt) 2021-11-02
EP3981766A1 (en) 2022-04-13
JP2018516250A (ja) 2018-06-21
RU2733741C2 (ru) 2020-10-06
CA2987321C (en) 2023-09-19
NZ737512A (en) 2024-09-27
PE20181083A1 (es) 2018-07-05
KR102664618B1 (ko) 2024-05-10
RU2017146408A (ru) 2019-07-02
TW201706250A (zh) 2017-02-16
PH12017502142A1 (en) 2018-06-11
MA43364A (fr) 2021-04-14
EP3302471B1 (en) 2021-08-25
MY186977A (en) 2021-08-26
CN107847498B (zh) 2021-04-13
US9796683B2 (en) 2017-10-24
CO2017013432A2 (es) 2018-05-21
HRP20211542T1 (hr) 2022-01-07
KR20180011274A (ko) 2018-01-31
ZA201707912B (en) 2019-05-29
JP6325760B1 (ja) 2018-05-16
US20180127378A1 (en) 2018-05-10
LT3302471T (lt) 2021-10-11
SI3302471T1 (sl) 2021-11-30
MA43364B1 (fr) 2021-11-30
MX2017015226A (es) 2018-02-19
MX379297B (es) 2025-03-10
IL255765B1 (en) 2023-06-01
CA2987321A1 (en) 2016-12-08
EP3302471A1 (en) 2018-04-11
DK3302471T3 (da) 2021-11-15
PH12017502142B1 (en) 2024-07-03
US20160347717A1 (en) 2016-12-01
US10851065B2 (en) 2020-12-01
JO3735B1 (ar) 2021-01-31
WO2016196337A1 (en) 2016-12-08
IL255765A (en) 2018-01-31
BR112017025546A2 (pt) 2018-08-07
CN113024466A (zh) 2021-06-25

Similar Documents

Publication Publication Date Title
BE2015C047I2 (ru)
CN303070913S (ru)
BR0008789B1 (ru)
BR0000126B1 (ru)
BR0000695B1 (ru)
BR0000763F1 (ru)
BR0001536B1 (ru)
BR0001684B1 (ru)
BR0001810B1 (ru)
BR0002033B1 (ru)
BR0002402B1 (ru)
BR0002435B1 (ru)
BR0002694B1 (ru)
BR0002802B1 (ru)
BR0002874B1 (ru)
BR0003166B1 (ru)
BR0003189B1 (ru)
BR0003208B1 (ru)
BR0003401B1 (ru)
BR0003686B1 (ru)
BR0003746B1 (ru)
BR0003751B1 (ru)
BR0003928B1 (ru)
BR0004687B1 (ru)
BR0005041B1 (ru)